Cellular studies have shown that in some cancers (e.g., melanoma, liver, stomach, breast cancer) NIS expression can be pharmacologically induced, e.g., by histone deacetylase inhibitors (HDAC inhibitors) and inhibition of MAPK and PI3K/Akt pathways [39]. The gene discussed is AKT1; the disease is cancer.